SynVivo

Executive Summary

SynVivo is a US-based biotechnology company pioneering advanced organ-on-a-chip platforms that replicate human tissue microenvironments with dynamic flow. Founded in 2009 and currently in pre-clinical stage, the company’s proprietary 3D microfluidic models provide human-relevant data for drug discovery, toxicology, and translational research. By offering a more physiologically accurate alternative to traditional 2D cell cultures and animal models, SynVivo addresses critical challenges in predicting drug efficacy and safety. Its platforms are applied across neuroscience, oncology, inflammation, lung biology, and toxicology, positioning the company at the forefront of the growing organ-on-a-chip market, which is driven by regulatory push for human-relevant testing and the need to reduce drug development costs and failure rates. With increasing adoption by pharmaceutical and academic labs, SynVivo is well-positioned to capitalize on the shift toward microphysiological systems. The company’s technology has the potential to accelerate preclinical screening, reduce animal testing, and improve clinical translation. Key upcoming milestones include potential strategic partnerships, regulatory endorsements, and platform expansions into new therapeutic areas. While still private and pre-revenue, SynVivo’s long-standing expertise and innovative portfolio make it an attractive candidate for investors seeking exposure to the next generation of drug development tools.

Upcoming Catalysts (preview)

• Q3 2026Announcement of major pharma partnership for oncology drug screening validation60% success
• Q4 2026Receipt of NIH grant to advance lung biology organ-on-a-chip models70% success
• Q2 2026Launch of new neurodegenerative disease organ-on-a-chip model50% success